Johnson & Johnson (NYSE:JNJ) is highlighted as one of the most profitable healthcare stocks to buy, with a price target raised to $250 by TD Cowen. Analysts expect growth in the company’s Pharmaceutical and Medical Devices segments, following Q4 revenue of $24.6 billion. BofA Securities slightly raised its price target to $221.

Founded in 1886, Johnson & Johnson (NYSE:JNJ) offers healthcare products globally through its Innovative Medicine and MedTech segments. While JNJ is seen as a solid investment, some believe AI stocks offer greater potential. Investors seeking undervalued AI stocks may find opportunities in the current market landscape.

Analysts are optimistic about Johnson & Johnson (NYSE:JNJ) following strong Q4 results, with revenue exceeding expectations. The company’s growth drivers and currency movements contribute to its financial stability. JNJ’s performance is praised by analysts, with a revised price target reflecting an upside potential of approximately 14%.

Read more at Yahoo Finance: Is Johnson & Johnson (JNJ) The Most Profitable Healthcare Stock To Buy?